Therefore, DNA repair proteins, XRCC1 and PARP1, have been associated with significantly aggressive clinical outcome of ovarian cancer patients and decreased cisplatin sensitivity in OC cells. This evidence concerns the gene XRCC1 and ovarian carcinoma.